Compare Freeport-McMoRan Inc (FCX) vs HCA Health Inc (HCA) Price & Performance

FCX trades at $58.30, down 5.92% over 24 hours, with a neutral technical signal and bearish moving averages. The stock has consistently beaten earnings estimates, with Q2 2026 expected EPS of $0.60. Revenue grew to $25.92B in 2025, with net income of $2.20B and a net margin of 10.34%. The company maintains strong cash flow from operations of $5.61B and a dividend of $0.15 per share payable in August 2026.

FCX presents a favorable outlook with robust earnings performance and analyst consensus pointing to a $72.94 price target, implying significant upside. However, risks include commodity price volatility, high capital expenditures, and debt levels. The stock's current valuation at a P/E of 32.26 may limit near-term gains if growth moderates.

HCA Healthcare (HCA) trades at $389.90, up 7.23% over the past 24 hours, with strong recent earnings beats but a bearish technical signal. The stock shows solid fundamentals with 2025 revenue of $75.60B and net income of $6.78B, supported by a P/E of 13.05 and net margin of 8.89%. However, recent news highlights guidance cuts due to payer mix shifts and rising uninsured patients, creating near-term headwinds.

The outlook is mixed: analyst consensus remains bullish with a $469.40 price target, but technical indicators and recent guidance reductions suggest caution. Key risks include margin compression and debt levels, while long-term growth drivers like capacity expansion and gene therapy research offer potential upside. Investors should weigh strong valuation metrics against operational challenges.